Rapamycin for Prevention of Chronic Graft-Versus-Host Disease
Status:
Terminated
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate feasibility, toxicity and efficacy of using
Rapamycin to prevent chronic graft-versus-host-disease (GVHD) during and after the tacrolimus
taper in recipients of allogeneic stem cell transplant.
Our hypothesis is that the T cells that can cause chronic GVHD are suppressed but not
eliminated by calcineurin inhibitors. Therefore, when the calcineurin inhibitors are
discontinued, the T cells may get activated and result in GVHD. Rapamycin on the other hand
will allow anergy formation and thus when discontinued, T cells should not get activated. The
schedule is designed to have therapeutic rapamycin levels as the tacrolimus is discontinued.
Rapamycin will be continued as a single agent for additional 4 weeks and be tapered off in
two weeks.